- Home
- TAVI vs CRBU Comparison
TAVI vs CRBU Comparison
Compare TAVI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAVI
- CRBU
- Stock Information
- Founded
- TAVI 2024
- CRBU 2011
- Country
- TAVI United States
- CRBU United States
- Employees
- TAVI N/A
- CRBU N/A
- Industry
- TAVI
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- TAVI
- CRBU Health Care
- Exchange
- TAVI Nasdaq
- CRBU Nasdaq
- Market Cap
- TAVI 164.0M
- CRBU 179.7M
- IPO Year
- TAVI 2024
- CRBU 2021
- Fundamental
- Price
- TAVI $10.35
- CRBU $2.34
- Analyst Decision
- TAVI
- CRBU Strong Buy
- Analyst Count
- TAVI 0
- CRBU 3
- Target Price
- TAVI N/A
- CRBU $6.67
- AVG Volume (30 Days)
- TAVI 20.0K
- CRBU 1.1M
- Earning Date
- TAVI 01-01-0001
- CRBU 11-05-2025
- Dividend Yield
- TAVI N/A
- CRBU N/A
- EPS Growth
- TAVI N/A
- CRBU N/A
- EPS
- TAVI 5.42
- CRBU N/A
- Revenue
- TAVI N/A
- CRBU $9,121,000.00
- Revenue This Year
- TAVI N/A
- CRBU $9.23
- Revenue Next Year
- TAVI N/A
- CRBU N/A
- P/E Ratio
- TAVI $1.91
- CRBU N/A
- Revenue Growth
- TAVI N/A
- CRBU N/A
- 52 Week Low
- TAVI $9.89
- CRBU $0.66
- 52 Week High
- TAVI $10.72
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- TAVI N/A
- CRBU 63.17
- Support Level
- TAVI N/A
- CRBU $2.17
- Resistance Level
- TAVI N/A
- CRBU $2.39
- Average True Range (ATR)
- TAVI 0.00
- CRBU 0.19
- MACD
- TAVI 0.00
- CRBU 0.04
- Stochastic Oscillator
- TAVI 0.00
- CRBU 92.96
About TAVI Tavia Acquisition Corp. Ordinary Shares
Tavia Acquisition Corp is a blank check company.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.